Skip to main content

Psoriasis clinical trials at UCSF
6 in progress, 2 open to new patients

  • Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

    open to eligible people ages 18 years and up

    This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.

    San Francisco, California

  • Single Cell Genomics of Psoriatic Skin

    open to eligible people ages 18 years and up

    The purpose of this study is to understand how genetics play a role in psoriasis. Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this study aims to find out how it affects genetic and protein expression in patients with psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry and RNA-sequencing protocol.

    San Francisco, California

  • A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

    Sorry, not yet accepting patients

    This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.

    San Francisco, California and other locations

  • Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

    Sorry, not yet accepting patients

    This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

    San Francisco, California and other locations

  • A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

    San Francisco, California and other locations

  • Chronic Plaque Psoriasis (Ps) Registry

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

    San Francisco, California and other locations

Last updated: